R&D | Cutting-edge science and innovative research

R&D

Q4 Clinical trials round-up: October to December 2025

We round up the key data and innovations in Q4 2025 - and what these likely presage for 2026’s R&D focus.

R&D

Big promises, hard work: What 2026 will demand from pharma

Eloise McLennan looks at a set of signals areas where pressure is building and 2026 looks set to demand more clarity, discipline, and follow-through.

R&D

Clinical research demands agile CROs

An emerging consensus across sponsors, investigators, and regulators is that agility must become a defining attribute of CRO performance.

News

CEPI steps in to fund Moderna's pandemic flu jab

Thanks to CEPI, Moderna's H5 bird flu vaccine can start a pivotal trial shelved after funding for the jab was pulled in the US by HHS Sec Kennedy.

News

Ambros' $125m for pain disorder drug, and other financings

Our latest crop of biofinancings has nine-figure rounds for Ambros, Atavistik, Orum, and Addition, with Link Cell and Aeovian also raising new funds.

News

Representation of Ascendis Pharma technology

Novo puts $285m into monthly GLP-1 based on Ascendis tech

Novo Nordisk has partnered with Ascendis Pharma on less frequently dosed drugs for obesity and other metabolic diseases, starting with a once-monthly GLP-1 receptor agonist.

News

Slide showing non-alcoholic fatty liver disease (NAFLD)

Novo Nordisk will file semaglutide for MASH next year

Novo Nordisk's GLP-1 receptor agonist semaglutide has shown efficacy as a treatment for metabolic dysfunction-associated steatohepatitis (MASH) in a phase 3 trial, potentially teeing up US

R&D

Partner Content

Europe’s Largest Industry-Led & Dedicated Gathering for mRNA...

The 4th mRNA-Based Therapeutics Summit Europe returns to Frankfurt, Germany as the industry’s premier forum dedicated to showcasing the hottest disease targets,

Debates & Insights

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Webinars

Sponsored

Synthetic control arms in clinical trials: Making it happen

Across the industry, pharma companies are turning to AI and real-world data to address many of the challenges of running clinical trials.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/live.png

Webinars

Sponsored

How synthetic control arms are changing clinical trials

Clinical trials are involved, expensive, and have been done largely the same way for decades but with today’s technology all that can change.

News

Fractured borderlines between flags of US, China, and North Korea

US BIOSECURE Act passed by Congress

The BIOSECURE Act, now part of the NDAA, will put in motion US government-wide restrictions on ‘biotechnology companies of concern'.

News

CEPI steps in to fund Moderna's pandemic flu jab

Thanks to CEPI, Moderna's H5 bird flu vaccine can start a pivotal trial shelved after funding for the jab was pulled in the US by HHS Sec Kennedy.

Press Releases

Views & Analysis

Touring Chiesi's vision for the future at the new Biotech Ce...

Following an invite to fly into Parma, Italy to witness first-hand the press launch of the considerable structure – black-painted and as yet under construction, gigantic cranes and all – th

News

Vir awarded $1 billion multi-year BARDA influenza contract

The US Government’s Biomedical Advanced Research and Development Authority (BARDA) has made an

Views & Analysis

R&D

Q4 Clinical trials round-up: October to December 2025

We round up the key data and innovations in Q4 2025 - and what these likely presage for 2026’s R&D focus.

R&D

Big promises, hard work: What 2026 will demand from pharma

Eloise McLennan looks at a set of signals areas where pressure is building and 2026 looks set to demand more clarity, discipline, and follow-through.

R&D

Clinical research demands agile CROs

An emerging consensus across sponsors, investigators, and regulators is that agility must become a defining attribute of CRO performance.

Deep Dive

R&D

R&D Contraceptive pills condoms and intrauterine device

Research and Development

R&D

Deep Dive: Research and Development 2025

Every breakthrough in medicine, every new treatment that changes lives, starts with research.

R&D

Breaking through financial barriers to clinical trials: How ...

R&D

Sponsored

Exploring the future: Opportunities and challenges in cell a...

Rare disease treatment poses distinct challenges for physicians, patients, caregivers, and pharma companies.

R&D

Sponsored

Beyond clinical: Boosting recruitment and retention with SDO...

The success of clinical trials hinges on a complex array of factors, many of which extend beyond traditional clinical care.

R&D

evolution of clinical research in the UK

Sponsored

The evolution of clinical research: Embracing new delivery m...

The UK is welcoming a new era of clinical trial delivery, evolving beyond the traditional site-centric approach to also embrace remote, decentralised, virtual, and hybrid trials and enablin

Podcasts

R&D

pharmaphorum podcast Episode 230, Benedict Cross, PhoreMost

Harnessing the cell's own degradation machinery, with Benedi...

Benedict Cross, Chief Technology Officer at PhoreMost, discusses targeted protein degradation.

R&D

pharmaphorum podcast Episode 227, Punit Dhillon, Skye Bioscience

On CB1s as an alternative to GLP-1s, with Punit Dhillon

In a new pharmaphorum podcast, Punit Dhillon, CEO of Skye Bioscience, discusses CB1 inhibitor antibodies in the obesity space.

R&D

pharmaphorum podcast Episode 225, Simon Kohl, Latent Labs

Towards a democratic era of medicine, with Simon Kohl

In a new episode, Simon Kohl discusses Latent Labs’ emergence from stealth, as well as protein design and drug discovery acceleration in more detail.

Video

R&D

Sponsored

Unlocking the future of obesity treatment

Obesity is more than a number on the scale, it’s a complex, malignant disease linked to diabetes, cardiovascular conditions, and even certain cancers.

R&D

Sponsored

Thermo Fisher Scientific on the value of an integrated appro...

In a new sponsored video, Thermo Fisher Scientific’s Alberto Fernández discusses the company's Accelerator Drug Development solution.

R&D

ESMO25: On partnerships between pharma and diagnostic develo...

Jane Li, Senior Director of Pharma CDx and CRO Partnership, Clinical Next Generation Sequencing Business, at Thermo Fisher Scientific discusses CDx.

White Papers

R&D

A man stood on a rock looking towards the horizon

Sponsored

A New Framework to Engineer Breakthrough Value for Medicines

A new white paper from Lumanity – ‘A New Framework to Engineer Breakthrough Value for Medicines: Value Inflection Points Across the Development Path’.

R&D